• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠外表现可能会增加克罗恩病患者发生其他肠外表现同步和异时发展的风险。

Extra intestinal manifestations may increase the risk of synchronous and metachronous development of other extraintestinal manifestations in patients with Crohn's disease.

作者信息

Ozkahraman Adnan, Kayar Yusuf, Dertli Ramazan, Konur Sevki, Kılıc Guner, Baran Bulent, Ormeci Asli Cifcibasi, Akyuz Filiz, Demir Kadir, Besisik Fatih, Kaymakoglu Sabahattin

机构信息

Department of Internal Medicine, Van Teaching and Research Hospital, Health Sciences University, Van, Turkey.

Division of Gastroenterology, Department of Internal Medicine, Van Teaching and Research Hospital, Health Sciences University, Van, Turkey.

出版信息

Sci Rep. 2025 Jul 1;15(1):20629. doi: 10.1038/s41598-025-07180-6.

DOI:10.1038/s41598-025-07180-6
PMID:40594471
Abstract

Although Crohn's disease (CD) affects the intestines, it is known to be a systemic disease rather than being limited to the intestines. Extra intestinal manifestations (EIMs) accompanying CD are reported at rates varying from 6 to 53%. While EIM negatively affects the quality of life of some patients, some EIMs, such as primary sclerosing cholangitis and thromboembolism, can be life-threatening. Although more than one EIM can occur simultaneously, the development of one EIM increases the probability of developing another EIM. There are few studies on how EIMs affect each other. The aim of this study was to examine the frequency of EIMs accompanying CD and their interactions with each other. This study included patients with CD who were under regular follow-up from March 1986 to October 2011. Accompanying EIMs and the time of development were recorded. The frequency of EIMs and their associations with each other were investigated. In total, 336 patients with CD (55.4% male) with a mean follow-up duration of 7.54 years (range, 6 months-25.4 years) were evaluated. At the time of CD diagnosis, 21.1% of the patients had at least one EIM, and at the end of the 25-year follow-up period, the prevalence of EIMs was 47.3%. The prevalence of multiple EIMs was 12.2% and 22.9% at the onset of CD and at the 25-year follow-up, respectively. Oral, joint 9.2%, respectively) were the most common EIMs. The development and skin involvement (32.4%, 24.7%, and of peripheral arthritis was significantly associated with axial spondiloarthropathy, skin involvement, ocular involvement, oral ulcers, and vascular thromboembolism (p < 0.05). There was a significant relationship between oral ulcers and peripheral arthritis, axial arthritis, skin involvement, ocular involvement, liver involvement and thromboembolism (p < 0.05). No significant relationship was detected between neurological involvement and any other EIMs. The development of EIMs in patients with CD may trigger the development of other EIMs during the course of the disease.

摘要

虽然克罗恩病(CD)累及肠道,但它是一种全身性疾病,而非局限于肠道。据报道,CD伴发的肠外表现(EIMs)发生率在6%至53%之间。虽然EIMs对部分患者的生活质量有负面影响,但一些EIMs,如原发性硬化性胆管炎和血栓栓塞,可能危及生命。虽然多种EIMs可能同时出现,但一种EIM的发生会增加出现另一种EIM的可能性。关于EIMs如何相互影响的研究较少。本研究的目的是调查CD伴发EIMs的频率及其相互作用。本研究纳入了1986年3月至2011年10月期间接受定期随访的CD患者。记录伴发的EIMs及其发生时间。调查EIMs的频率及其相互关联。共评估了336例CD患者(男性占55.4%),平均随访时间为7.54年(范围为6个月至25.4年)。在CD诊断时,21.1%的患者至少有一种EIMs,在25年随访期结束时,EIMs的患病率为47.3%。在CD发病时和25年随访时,多种EIMs的患病率分别为12.2%和22.9%。口腔、关节和皮肤受累(分别为32.4%、24.7%和9.2%)是最常见的EIMs。外周关节炎的发生与中轴型脊柱关节炎、皮肤受累、眼部受累、口腔溃疡和血管血栓栓塞显著相关(p<0.05)。口腔溃疡与外周关节炎、中轴关节炎、皮肤受累、眼部受累、肝脏受累和血栓栓塞之间存在显著关系(p<0.05)。未发现神经受累与任何其他EIMs之间存在显著关系。CD患者中EIMs的发生可能在疾病过程中引发其他EIMs的发生。

相似文献

1
Extra intestinal manifestations may increase the risk of synchronous and metachronous development of other extraintestinal manifestations in patients with Crohn's disease.肠外表现可能会增加克罗恩病患者发生其他肠外表现同步和异时发展的风险。
Sci Rep. 2025 Jul 1;15(1):20629. doi: 10.1038/s41598-025-07180-6.
2
Vitamin D for the treatment of inflammatory bowel disease.维生素 D 治疗炎症性肠病。
Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD011806. doi: 10.1002/14651858.CD011806.pub2.
3
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.干预措施用于克罗恩病和炎症性肠病的腹痛管理。
Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2.
4
A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.TNF-α 抑制剂(阿达木单抗和英夫利昔单抗)治疗克罗恩病的系统评价和经济评估。
Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060.
5
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
6
Ocular Manifestations of Paediatric Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.儿科炎症性肠病的眼部表现:系统评价和荟萃分析。
J Crohns Colitis. 2018 Jun 28;12(7):870-879. doi: 10.1093/ecco-jcc/jjy029.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
9
Systemic and topical antibiotics for chronic rhinosinusitis.用于慢性鼻-鼻窦炎的全身及局部用抗生素
Cochrane Database Syst Rev. 2016 Apr 26;4(4):CD011994. doi: 10.1002/14651858.CD011994.pub2.
10
Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).自闭症谱系障碍(ASD)中易怒、攻击行为和自我伤害的药物干预。
Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.

本文引用的文献

1
Risk factors associated with progression to intestinal complications of Crohn disease.与克罗恩病肠道并发症进展相关的风险因素。
Chin Med J (Engl). 2019 Oct 20;132(20):2423-2429. doi: 10.1097/CM9.0000000000000489.
2
Clinical outcomes and risk factors of secondary extraintestinal manifestation in ulcerative colitis: results of a multicenter and long-term follow-up retrospective study.溃疡性结肠炎继发肠外表现的临床结局及危险因素:一项多中心长期随访回顾性研究的结果
PeerJ. 2019 Jun 21;7:e7194. doi: 10.7717/peerj.7194. eCollection 2019.
3
The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults.
儿童与成人炎症性肠病肠外表现的差异。
Transl Pediatr. 2019 Jan;8(1):4-15. doi: 10.21037/tp.2019.01.06.
4
Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis.炎症性肠病的肠外表现——流行病学、遗传学和发病机制。
Expert Rev Gastroenterol Hepatol. 2019 Apr;13(4):307-317. doi: 10.1080/17474124.2019.1574569. Epub 2019 Feb 20.
5
Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients.韩国炎症性肠病患者的肠外表现患病率。
PLoS One. 2018 Jul 10;13(7):e0200363. doi: 10.1371/journal.pone.0200363. eCollection 2018.
6
Skin Manifestations of Inflammatory Bowel Disease.炎症性肠病的皮肤表现。
Clin Rev Allergy Immunol. 2017 Dec;53(3):413-427. doi: 10.1007/s12016-017-8617-4.
7
Microbiome-Linked Crosstalk in the Gastrointestinal Exposome towards Host Health and Disease.胃肠道暴露组中与微生物群相关的串扰对宿主健康和疾病的影响
Pediatr Gastroenterol Hepatol Nutr. 2016 Dec;19(4):221-228. doi: 10.5223/pghn.2016.19.4.221. Epub 2016 Dec 28.
8
The safety of vedolizumab for ulcerative colitis and Crohn's disease.维多珠单抗用于溃疡性结肠炎和克罗恩病的安全性。
Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18.
9
Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.一大群希腊炎症性肠病患者肠外表现的患病率及特征
J Crohns Colitis. 2016 Apr;10(4):429-36. doi: 10.1093/ecco-jcc/jjv232. Epub 2015 Dec 30.
10
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease.首部关于炎症性肠病肠外表现的欧洲循证共识
J Crohns Colitis. 2016 Mar;10(3):239-54. doi: 10.1093/ecco-jcc/jjv213. Epub 2015 Nov 27.